{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:31:53Z","timestamp":1724473913105},"reference-count":21,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1248\/bpb.b20-00984","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T22:07:45Z","timestamp":1617228465000},"page":"474-477","source":"Crossref","is-referenced-by-count":4,"title":["Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study"],"prefix":"10.1248","volume":"44","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tamaki","sequence":"additional","affiliation":[{"name":"KKR Sapporo Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NTT Medical Center Sapporo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tokutome","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sapporo Higashi Tokushukai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Cancer Center, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. <i>N. Engl. J. Med.<\/i>, <b>357<\/b>, 39\u201351 (2007).","DOI":"10.1056\/NEJMra043186"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, Choo MJ, Chang SJ. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. <i>MAbs<\/i>, <b>10<\/b>, 547\u2013571 (2018).","DOI":"10.1080\/19420862.2018.1440170"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Slamon DJ, Godolphin W, Jones LA, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A, et. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. <i>Science<\/i>, <b>244<\/b>, 707\u2013712 (1989).","DOI":"10.1126\/science.2470152"},{"key":"4","unstructured":"4) Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. <i>Ann. Oncol.<\/i>, <b>19<\/b>, 1523\u20131529 (2008)."},{"key":"5","unstructured":"5) Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. <i>Oncologist<\/i>, <b>14<\/b>, 320\u2013368 (2009)."},{"key":"6","unstructured":"6) Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R\u00fcschoff J, Kang YK. Trastuzumab in combination with chemotherapy <i>versus<\/i> chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet<\/i>, <b>376<\/b>, 687\u2013697 (2010)."},{"key":"7","unstructured":"7) Guideline on similar biological medicinal products [draft guidance]. European Medicines Agency. 2013; Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/05\/WC500142978.pdf [Last accessed 14 January 2020]"},{"key":"8","unstructured":"8) Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncol.<\/i>, <b>18<\/b>, 917\u2013928 (2017)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. <i>Cancer Chemother. Pharmacol.<\/i>, <b>81<\/b>, 505\u2013514 (2018).","DOI":"10.1007\/s00280-017-3510-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Esteva FJ, Saeki T, Kim H, Stebbing J. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. <i>Future Oncol.<\/i>, <b>14<\/b>, 1909\u20131919 (2018).","DOI":"10.2217\/fon-2017-0679"},{"key":"11","unstructured":"11) Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 <i>versus<\/i> reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. <i>Cancer Chemother. Pharmacol.<\/i>, <b>84<\/b>, 839\u2013847 (2019)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. <i>Oncologist<\/i>, <b>13<\/b>, 725\u2013732 (2008).","DOI":"10.1634\/theoncologist.2008-0012"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Price L, Brunt AM. Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? <i>Eur. J. Hosp. Pharm.<\/i>, <b>25<\/b>, 331\u2013333 (2018).","DOI":"10.1136\/ejhpharm-2016-001155"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortob\u00e1gyi GN, Barnett CM. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. <i>Oncologist<\/i>, <b>19<\/b>, 228\u2013234 (2014).","DOI":"10.1634\/theoncologist.2013-0286"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Oh SY, Lee S, Huh SJ, Lee J, Kim ST, Park SH, Lim HY, Kang WK, Kang BW, Kim JG, Lee HJ, Kim JH, Kang JH, Kim H. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemother. Pharmacol.<\/i>, <b>83<\/b>, 501\u2013508 (2019).","DOI":"10.1007\/s00280-018-3753-y"},{"key":"16","unstructured":"16) Genentech Inc. \u201cHighlights of prescribing information. Herceptin<sup>\u00ae<\/sup> (trastuzumab) for injection, for intravenous use.\u201d: \u2039https:\/\/www.gene.com\/download\/pdf\/herceptin_prescribing.pdf\u203a, accessed 22 June, 2020."},{"key":"17","unstructured":"17) Aogi K, Takeuchi H, Saeki T, <i>et al.<\/i> Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. <i>Int. J. Clin. Oncol.<\/i>, <b>26<\/b>, 1\u201317 (2021)."},{"key":"18","unstructured":"18) Taxol<sup>\u00ae<\/sup> (paclitaxel) [package insert on the internet]. \u201cBristol-Myers Squibb, 2018.\u201d: \u2039http:\/\/file.bmshealthcare.jp\/bmshealthcare\/pdf\/package\/TX1802.pdf\u203a, accessed 25 Dec., 2020."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Wu J, Qiu K, Zhu J, Li J, Lin Y, He Z, Li G. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade. <i>Breast<\/i>, <b>24<\/b>, 699\u2013704 (2015).","DOI":"10.1016\/j.breast.2015.08.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. <i>J. Clin. Oncol.<\/i>, <b>20<\/b>, 719\u2013726 (2002).","DOI":"10.1200\/JCO.2002.20.3.719"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G, Webb A. Infusion of trastuzumab maintenance doses over 30 minutes. <i>Ann. Oncol.<\/i>, <b>19<\/b>, 1509\u20131510 (2008).","DOI":"10.1093\/annonc\/mdn390"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-00984\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:29:54Z","timestamp":1617420594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-00984\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00984","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}